Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
26 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Neurotec Pharma SL - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Neurotec Pharma SL - Product Pipeline Review - 2014', provides an overview of the Neurotec Pharma SL's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Neurotec Pharma SL's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Neurotec Pharma SL including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Neurotec Pharma SL's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Neurotec Pharma SL's pipeline products Reasons to buy - Evaluate Neurotec Pharma SL's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Neurotec Pharma SL in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Neurotec Pharma SL's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Neurotec Pharma SL and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Neurotec Pharma SL - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Neurotec Pharma SL and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Neurotec Pharma SL Snapshot 5 Neurotec Pharma SL Overview 5 Key Information 5 Key Facts 5 Neurotec Pharma SL - Research and Development Overview 6 Key Therapeutic Areas 6 Neurotec Pharma SL - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Neurotec Pharma SL - Pipeline Products Glance 11 Neurotec Pharma SL - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Neurotec Pharma SL - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Neurotec Pharma SL - Drug Profiles 13 diazoxide 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 NT-CC-017 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 NT-FV-007 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 NT-KC-005 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 NT-KO-009 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 NT-KO-012 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Neurotec Pharma SL - Pipeline Analysis 20 Neurotec Pharma SL - Pipeline Products by Target 20 Neurotec Pharma SL - Pipeline Products by Route of Administration 21 Neurotec Pharma SL - Pipeline Products by Molecule Type 22 Neurotec Pharma SL - Pipeline Products by Mechanism of Action 23 Neurotec Pharma SL - Locations And Subsidiaries 24 Head Office 24 Appendix 25 Methodology 25 Coverage 25 Secondary Research 25 Primary Research 25 Expert Panel Validation 25 Contact Us 26 Disclaimer 26
List of Tables Neurotec Pharma SL, Key Information 5 Neurotec Pharma SL, Key Facts 5 Neurotec Pharma SL - Pipeline by Indication, 2014 8 Neurotec Pharma SL - Pipeline by Stage of Development, 2014 9 Neurotec Pharma SL - Monotherapy Products in Pipeline, 2014 10 Neurotec Pharma SL - Phase II, 2014 11 Neurotec Pharma SL - Preclinical, 2014 12 Neurotec Pharma SL - Pipeline by Target, 2014 20 Neurotec Pharma SL - Pipeline by Route of Administration, 2014 21 Neurotec Pharma SL - Pipeline by Molecule Type, 2014 22 Neurotec Pharma SL - Pipeline Products by Mechanism of Action, 2014 23
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.